J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 M e d i c a l u s e s
2 S i d e e f f e c t s
3 I n t e r a c t i o n s
4 P h a r m a c o l o g y
T o g g l e P h a r m a c o l o g y s u b s e c t i o n
4 . 1 M e c h a n i s m o f a c t i o n
4 . 2 P h a r m a c o k i n e t i c s
5 H i s t o r y
6 S o c i e t y a n d c u l t u r e
T o g g l e S o c i e t y a n d c u l t u r e s u b s e c t i o n
6 . 1 E c o n o m i c s
6 . 2 L e g a l s t a t u s
6 . 3 N a m e s
7 R e f e r e n c e s
T o g g l e t h e t a b l e o f c o n t e n t s
E r e n u m a b
1 0 l a n g u a g e s
● ا ل ع ر ب ي ة ● C a t a l à ● D e u t s c h ● E s p a ñ o l ● F r a n ç a i s ● I t a l i a n o ● N o r s k b o k m å l ● ଓ ଡ ଼ ି ଆ ● P o r t u g u ê s ● T i ế n g V i ệ t
E d i t l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
( R e d i r e c t e d f r o m A i m o v i g )
Erenumab , sold under the brand name Aimovig , is a medication which blocks the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine .[3] [4] [5] subcutaneous injection .[3] [4]
Erenumab, which was developed by Amgen and Novartis ,[5] Food and Drug Administration .[6] million prescriptions.[7] [8]
Medical uses [ edit ]
Erenumab is indicated for the prevention of migraine in adults.[3] [4]
Side effects [ edit ]
Common side effects are constipation , pruritus , muscle spasms , as well as mild and mostly transient reactions at the injection site .[4] [9]
Interactions [ edit ]
Erenumab was shown not to interact with ethinylestradiol , norgestimate or the migraine drug sumatriptan . It is expected to generally have a low potential for interactions because it is not metabolized by cytochrome P450 enzymes.[9]
Pharmacology [ edit ]
Mechanism of action [ edit ]
Erenumab is a fully human monoclonal antibody blocking the calcitonin gene-related peptide receptor (CGRPR).[3] [10] [11]
Pharmacokinetics [ edit ]
After subcutaneous injection , the erenumab has an estimated bioavailability of 82%. Highest blood plasma concentrations are reached after four to six days. Like other proteins, the substance is degraded by proteolysis to small peptides and amino acids . It has an elimination half-life of 28 days.[9]
History [ edit ]
Erenumab was developed by Amgen Inc. in conjunction with Novartis .[5]
In the phase III STRIVE clinical trial 955 patients were divided into three groups in a 1:1:1 ratio. Each group was injected subcutaneously monthly with 0, 70 or 140 mg erenumab over a period of 6 months. The results were measured as mean monthly migraine days in months 4, 5, and 6. At baseline the patients experienced between 4 and 14 migraine days per month with an average of 8.3. The medication significantly reduced the number of migraine days per month by 3.2 in the 70-mg group and 3.7 in the 140-mg group, versus 1.8 in the placebo (0-mg) group.[5] [12]
Society and culture [ edit ]
Economics [ edit ]
As of 2018, the list price was reported to be US$6,900 per year.[13]
In the United Kingdom, Erenumab was approved by the Scottish Medicines Consortium , but the National Institute for Health and Care Excellence rejected the drug on the basis that its cost-effectiveness was not sufficiently proven.[14] [15]
Legal status [ edit ]
The United States Food and Drug Administration approved the medication for the preventive treatment of migraine in adults in May 2018. It was the first CGRPR antagonist to be approved.[6] [4] [16]
Erenumab is the international nonproprietary name and the United States Adopted Name .[17] [18]
References [ edit ]
^ a b c d e "Aimovig- erenumab-aooe injection Aimovig- erenumab-aooe injection, solution" . DailyMed . 19 August 2022. Archived from the original on 5 July 2022. Retrieved 29 September 2022 .
^ a b c d e f "Aimovig EPAR" . European Medicines Agency (EMA)Archived from the original on 17 October 2020. Retrieved 4 May 2020 .
^ a b c d Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. (November 2017). "A Controlled Trial of Erenumab for Episodic Migraine" . The New England Journal of Medicine . 377 (22 ): 2123–2132. doi :10.1056/NEJMoa1705848 PMID 29171821 .
^ a b "FDA Approves First-in-Class Drug Erenumab (Aimovig) for Migraine Prevention" . Medscape Archived from the original on 25 September 2019. Retrieved 21 May 2018 .
^ "The Top 300 of 2020" . ClinCalc . Retrieved 7 October 2022 .
^ "Erenumab - Drug Usage Statistics" . ClinCalc . Retrieved 7 October 2022 .
^ a b c "Aimovig: EPAR - Product Information" (PDF) . European Medicines Agency . 8 August 2018. Archived (PDF) from the original on 6 October 2018. Retrieved 2 May 2019 .
^ "Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig (erenumab) For Migraine Patients With Multiple Treatment Failures" (Press release). Amgen. 17 April 2018. Archived from the original on 11 November 2020. Retrieved 29 September 2022 – via PR Newswire.
^ Edvinsson L (December 2018). "CGRP Antibodies as Prophylaxis in Migraine" . Cell . 175 (7 ): 1719. doi :10.1016/j.cell.2018.11.049 PMID 30550780 .
^ "Erenumab to prevent migraine: results from phase III STRIBE" Archived 13 August 2018 at the Wayback Machine , Pharma World , 14 December 2017.
^ Kolata G (17 May 2018). "F.D.A. Approves First Drug Designed to Prevent Migraines" . The New York Times Archived from the original on 11 May 2020. Retrieved 26 September 2019 .
^ Gallagher J (26 September 2019). " . BBC News Online Archived from the original on 31 July 2021. Retrieved 26 September 2019 .
^ "New migraine drug not cost-effective NICE says in draft guidance" . NICE . Archived from the original on 1 November 2020. Retrieved 26 September 2019 .
^ "First drug to prevent chronic migraines approved by EU" . The Guardian Archived from the original on 19 September 2018. Retrieved 19 September 2018 .
^ "Statement On A Nonproprietary Name Adopted By The USAN Council - Erenumab" (PDF) . American Medical Association . 24 November 2015. Archived (PDF) from the original on 4 November 2018. Retrieved 4 November 2018 .
^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF) . WHO Drug Information . 30 2 ). Archived (PDF) from the original on 5 February 2018. Retrieved 30 September 2022 .
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=Erenumab&oldid=1228623369 " C a t e g o r i e s : ● A n t i m i g r a i n e d r u g s ● C a l c i t o n i n g e n e - r e l a t e d p e p t i d e r e c e p t o r a n t a g o n i s t s ● M o n o c l o n a l a n t i b o d i e s ● A m g e n ● D r u g s d e v e l o p e d b y N o v a r t i s H i d d e n c a t e g o r i e s : ● W e b a r c h i v e t e m p l a t e w a y b a c k l i n k s ● A r t i c l e s w i t h s h o r t d e s c r i p t i o n ● S h o r t d e s c r i p t i o n m a t c h e s W i k i d a t a ● U s e d m y d a t e s f r o m D e c e m b e r 2 0 1 9 ● D r u g s w i t h n o n - s t a n d a r d l e g a l s t a t u s ● C h e m i c a l s t h a t d o n o t h a v e a C h e m S p i d e r I D a s s i g n e d ● A r t i c l e s w i t h o u t I n C h I s o u r c e ● A r t i c l e s c o n t a i n i n g u n v e r i f i e d c h e m i c a l i n f o b o x e s ● D r u g s t h a t a r e a m o n o c l o n a l a n t i b o d y
● T h i s p a g e w a s l a s t e d i t e d o n 1 2 J u n e 2 0 2 4 , a t 0 7 : 3 3 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
